Onychomycosis and diabetes

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 10, 2009, Pages 1119-1122

  Cathcart, S ^a   Cantrell, W ^a   Elewski, Be ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Diabetes; Onychomycosis

Indexed keywords

AMOROLFINE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CICLOPIROX; CISAPRIDE; CYCLOSPORIN; FLUCONAZOLE; GLIBENCLAMIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LEVACETYLMETHADOL; METFORMIN; MONOAMINE OXIDASE INHIBITOR; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PIMOZIDE; QUINIDINE; RIFABUTIN; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TERBINAFINE; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

CANDIDA; COMORBIDITY; CUSHING DISEASE; DIABETES MELLITUS; DIABETIC FOOT; DRUG CONTRAINDICATION; DRUG EFFICACY; FOOT CARE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SIDE EFFECT; TASTE; TREATMENT PLANNING; VULNERABLE POPULATION;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; DIABETES COMPLICATIONS; HUMANS; MORPHOLINES; NAPHTHALENES; ONYCHOMYCOSIS; PYRIDONES;

EID: 70349145835     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03225.x     Document Type: Review

References (27)

1. Gupta AK, Konnikov N, MacDonald P et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicenter survey. Br J Dermatol 1998 139 : 665 671.
2. Chang SJ, Hsu SC, Tien KJ et al. Metabolic syndrome associated with toenail onychomycosis in Taiwanese with diabetes mellitus. Int J Dermatol 2008 47 : 467 472.
3. Fard AS, Esmaelzadeh M, Larijani B. Assessment and treatment of diabetic foot ulcer. Int J Clin Pract 2007 61 : 1931 1938.
4. Nather A, Bee CS, Huak CY et al. Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complications 2008 22 : 77 82.
5. Boyko EJ, Ahroni JH, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care 2006 29 : 1202 1207.
6. Rich P. Onychomycosis and tinea pedis in patients with diabetes. J Am Acad Dermatol 2000 43 : 130 134.
7. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998 11 : 415 429.
8. Janes GR. Ambulatory medical care for diabetics. In : Diabetes in America, 2nd ed. National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468. 1995 : 541 551.
9. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada-a multicenter survey of 2001 patients. Int J Dermatol 1997 36 : 783 787.
10. Alteras I, Saryt E. Prevalence of pathogenic fungi in the toe-webs and toe-nails of diabetic patients. Mycopathologia 1979 67 : 157 159.
11. Product Monograph: Sporanox capsules. Prescribing information. Janssen [online]. Available from URL. http://www.janssen-ortho.com/JOI/pdf-files/ sporanoxcaps-E.pdf (last accessed: August 2008).
12. Albreski DA, Gross EG. The safety of itraconazole in the diabetic population. J Am Podiatr Med Assoc 1999 89 : 339 345.
13. Verspeelt J, Marynissen G, Gupta AK, De Doncker P. Safety of itraconazole in diabetic patients. Dermatology 1999 198 : 382 384.
14. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 2006 20 : 1188 1193.
15. Hay RJ, Baran R, Moore MK, Wilkinson JD. Candida onychomycosis - an evaluation of the role of Candida species in nail disease. Br J Dermatol 1988 118 : 47 58.
16. Hostetter MK. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 1990 March 39 (3 271 275.
17. Daniel CR 3rd, Elewski BE. Candida as a nail pathogen in healthy patients. J Miss State Med Assoc 1995 36 : 379 381.
18. Clayton YM. Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol 1992 17 (Suppl. 1 37 40.
19. Product Information: Diflucan. Pfizer [online]. Availabel from URL. http://media.pfizer.com/files/products/uspi-diflucan.pdf (last accessed: August 2008)
20. Scher RK, Breneman D, Rich P et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998 38 : S77 S86.
21. Drake L, Babel D, Stewart DM et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998 38 : S87 S94.
22. Vickers AE, Sinclair JR, Zollinger M et al. Multiple cytochrome P-450 s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999 27 : 1029 1038.
23. Product Information: Lamisil. Novartis [online]. Available at URL. http://www.pharma.us.novartis.com/product/pi/pdf/Lamisil-tablets.pdf (last accessed: August 2008)
24. Farkas B, Paul C, Dobozy A, Hunyadi J, Horváth A, Fekete G. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 2002 146 : 254 260.
25. Brenner MA, Harkless LB, Mendicino RW, Page JC. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study. J Am Podiatr Med Assoc 2007 97 : 195 202.
26. Gupta AK, Joseph WS. Ciclopirox 8% nail laquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc 2000 90 : 495 501.
27. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992 184 (Suppl. 1 21 24.